1 Cardiology Department, CHU La Timone, Medical School of Marseilles, Marseilles, France 2 Epidemiology and Statistics Department, CHU La Timone, Medical School of Marseilles, Marseilles, France 3 ...
In summary, this study showed that the effects of the MPTP reduced the number of cardiomyocytes in the mouse left ventricle without changing the ventricular volume ... PMid:10647607> Van Vré E.A., Van ...
Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. "Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3™ LVAD, advancing our commitment to ...
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients Cadrenal Therapeutics ...
Pham, Chief Executive Officer, Cadrenal Therapeutics, Inc. "Together, we have a unique opportunity to evaluate tecarfarin in combination with the HeartMate 3™ LVAD, advancing our commitment to ...
Strengthens the Potential for Improved Patient Outcomes through Improvements in the Quality of Anticoagulation, Enhancing Hemocompatibility in HeartMate 3™ LVAD patients PONTE VEDRA, Fla.--(BUSINESS ...
to support Cadrenal’s pivotal TECarfarin Anticoagulation and Hemocompatibility with Left Ventricular Assist Devices (TECH-LVAD) trial.
NEW HAVEN, Conn. (WTNH) — A slam dunk in heart care innovation! Hartford HealthCare’s LVAD team is bringing together a day of friendly basketball competition and the power of LVAD technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback